{
  "trial_id": "NCT02196701",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, duration of psoriasis, baseline Physician's Global Assessment (PGA) score, baseline Psoriasis Area Severity Index (PASI) score, previous response to adalimumab monotherapy, history of chronic plaque psoriasis, general health status, pregnancy status, tuberculosis screening results, liver function tests (AST, ALT), serum total bilirubin levels, creatinine levels, hepatitis B or C serology, history of significant medical conditions (hematologic, renal, liver, CNS demyelinating disease, malignancy, infections, immune deficiency), alcohol usage history.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Duration of Psoriasis",
          "duration of psoriasis"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race/Ethnicity"
      ],
      "remaining_candidate_features": [
        "baseline Physician's Global Assessment (PGA) score",
        "baseline Psoriasis Area Severity Index (PASI) score",
        "previous response to adalimumab monotherapy",
        "history of chronic plaque psoriasis",
        "general health status",
        "pregnancy status",
        "tuberculosis screening results",
        "liver function tests (AST, ALT)",
        "serum total bilirubin levels",
        "creatinine levels",
        "hepatitis B or C serology",
        "history of significant medical conditions (hematologic, renal, liver, CNS demyelinating disease, malignancy, infections, immune deficiency)",
        "alcohol usage history"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Duration of Psoriasis, Baseline Psoriasis Area Severity Index (PASI), Baseline Physician's Global Assessment (PGA), Body Mass Index, Prior Psoriasis Treatments, Baseline Liver Function Tests (AST, ALT), Baseline Serum Creatinine, Baseline Total Bilirubin, Baseline Hepatitis B and C Serology,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Duration of Psoriasis",
          "Duration of Psoriasis"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Baseline Psoriasis Area Severity Index (PASI)",
        "Baseline Physician's Global Assessment (PGA)",
        "Body Mass Index",
        "Prior Psoriasis Treatments",
        "Baseline Liver Function Tests (AST, ALT)",
        "Baseline Serum Creatinine",
        "Baseline Total Bilirubin",
        "Baseline Hepatitis B and C Serology"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Psoriasis Area Severity Index (PASI), Physician's Global Assessment (PGA), Duration of Psoriasis, Previous Psoriasis Treatment, Concomitant Medications.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Duration of Psoriasis",
          "Duration of Psoriasis"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Body Mass Index",
        "Psoriasis Area Severity Index (PASI)",
        "Physician's Global Assessment (PGA)",
        "Previous Psoriasis Treatment",
        "Concomitant Medications"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, weight, body mass index (BMI), duration of psoriasis, Physician's Global Assessment (PGA) score, Psoriasis Area Severity Index (PASI) score, prior treatment with adalimumab, prior treatment with methotrexate, concomitant medications, medical history (including history of malignancy, tuberculosis, and central nervous system demyelinating disease).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Duration of Psoriasis",
          "duration of psoriasis"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "weight",
        "body mass index (BMI)",
        "Physician's Global Assessment (PGA) score",
        "Psoriasis Area Severity Index (PASI) score",
        "prior treatment with adalimumab",
        "prior treatment with methotrexate",
        "concomitant medications",
        "medical history (including history of malignancy, tuberculosis, and central nervous system demyelinating disease)."
      ]
    }
  }
}